Procyrion Hires Andrew Davis as New Chief Commercial Officer

Procyrion Appoints New Chief Commercial Officer

Procyrion™, Inc., a company focused on enhancing patient outcomes for those suffering from cardiac and renal issues, has recently announced the appointment of Andrew Davis as Chief Commercial Officer. This decision marks a significant step for the company as it aims to improve its market strategies and accelerate the development of its innovative therapy, the Aortix™ system.

Andrew Davis brings invaluable experience to Procyrion, having a solid background in the medical technology field. His primary responsibility will be to advance the therapy development initiatives that are crucial for increasing trial enrollment in Procyrion's pivotal DRAIN-HF IDE trial. This trial is particularly focused on patients dealing with diuretic-resistant heart failure problems—a significant unmet medical need.

In his new role, Davis will oversee several vital components including: engaging key opinion leaders (KOLs), developing podium strategies, and advancing early market initiatives crucial for the commercialization of the Aortix percutaneous mechanical circulatory support (pMCS) device. Eric S. Fain, MD, the President and CEO of Procyrion, emphasized the importance of Davis’s extensive cardiovascular expertise, stating, “Andy’s deep cardiovascular experience and proven track record of launching category-creating therapies makes him an exceptional addition to the company.”

The Aortix device represents a breakthrough in the treatment of acute decompensated heart failure, utilizing a catheter-deployed mechanism designed to enhance blood flow to the kidneys while simultaneously alleviating the heart's workload. This innovative pump operates without a valve, leveraging a natural mechanism to deliver therapeutic effects on patients suffering from cardiac and renal complications.

With a notable career history, Andrew Davis previously served as the Chief Commercial Officer at Silk Road Medical, where he directed the successful launch of a pioneering therapy for carotid artery disease. Additionally, he has demonstrated expertise during his extensive 15-year tenure at Medtronic, taking on leadership roles across various sales organizations related to cardiac and vascular therapies. His diverse experience covers multiple areas including structural heart treatments and advanced wound care.

Davis expresses enthusiasm about joining Procyrion, highlighting the urgent need for novel solutions for patients struggling with diuretic-resistant heart failure. He believes the Aortix pump presents a promising new option that could significantly improve patient outcomes. His vision to work closely with clinical teams and healthcare providers will help expand understanding of the therapy while laying a strong foundation for its future market introduction.

Overall, the inclusion of Andrew Davis as Chief Commercial Officer signifies Procyrion’s commitment to pioneering efforts in medical technology solutions for heart and renal conditions. The company remains focused on engaging with stakeholders and expanding its clinical trials to ensure more patients can eventually benefit from the innovative capabilities of the Aortix device.

Procyrion, Inc. is dedicated to redefining treatment pathways for patients with specific medical needs, continuously striving to fulfill the unmet requirements in the field of cardiac and renal impairment. Understanding the complexities involved in these conditions, the company aims to offer solutions that are not only effective but also transformative in nature. For those interested in following Procyrion’s journey or learning more about their devices, further information can be accessed through their official website: www.procyrion.com.